A coronavirus antiviral candidate hit Ebola in the lab. How far can Decoy Therapeutics take it?
Decoy Therapeutics reports early Ebola Zaire activity, but potency data, animal validation and funding will determine the D-MAV program.
Pharma & Biotech
Pharma & Biotech
FDA maintains constructive stance as Island Pharmaceuticals progresses Galidesivir clinical development
Island Pharmaceuticals Limited has confirmed that the United States Food and Drug Administration (FDA) continues to evaluate its most recent regulatory submission related to Galidesivir, the company’s clinical-stage antiviral candidate being advanced under the Animal Rule pathway. In correspondence dated 2 January 2026, the regulator informed the Australian biotech firm that additional time is required